Latest news with #Medeiros
Time of India
7 days ago
- Health
- Time of India
GLP-1 obesity drugs may boost low testosterone
London: GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes , researchers reported in San Francisco at ENDO 2025, the Endocrine Society's annual meeting. Weight loss from lifestyle changes or bariatric surgery is known to boost testosterone levels, but the impact of anti-obesity medications has not been widely investigated, study leader Dr. Shellsea Portillo Canales of SSM Health St. Louis University Hospital in Missouri said in a statement. Portillo Canales and colleagues tracked 110 men with obesity - many also with type 2 diabetes - who were being treated with semaglutide, dulaglutide or tirzepatide, the active ingredients in Novo Nordisk's Wegovy and Ozempic or Eli Lilly's Trulicity, Mounjaro, and Zepbound. The average age was 54. None of the men were receiving other testosterone-boosting medications. During 18 months of treatment, the proportion of men with testosterone levels in the normal range rose from 53% to 77%. Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, strength and red blood cell production. In the current study, the greater the weight loss, the greater the improvement in testosterone levels, the researchers found. While the study cannot prove GLP-1 drugs caused low testosterone levels to normalize, it does show a direct correlation, Portillo Canales noted. INTERMITTENT ACCESS TO GLP-1 DRUGS STILL YIELDS WEIGHT LOSS Popular GLP-1 anti-obesity medications are effective for weight loss even when treatment is inconsistent, new findings suggest. Patients often face challenges in accessing these medications - such as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Zepbound and Mounjaro - due to supply shortages and insurance coverage obstacles, study leader Kaelen Medeiros of privately held weight-loss company Calibrate in New York said in a statement. Medeiros and colleagues looked at how interruptions to GLP-1 medication access over the course of two years impacted weight-loss outcomes in 6,392 clients of Calibrate's online metabolic health program. Along with the drugs, the program also included intensive lifestyle interventions and coaching on diet, exercise, sleep and emotional health. Overall, 72.5% of participants experienced at least one disruption in their GLP-1 treatment and 11.1% had multiple disruptions, Medeiros reported at ENDO 2025. Participants who faced access issues reported a 13.7% weight loss within 12 months and a 14.9% loss within 24 months, on average. Those without treatment interruptions reported a 17% weight loss in 12 months and 20.1% in 24 months, on average. Even those who received no more than four treatments over 12 months also achieved clinically significant weight loss, with more than 10% change in body weight on average. "While unpredictable GLP-1 medication access is frustrating, the good news is that our research shows effective weight loss can still be achieved if paired with appropriate lifestyle changes and coaching support," Medeiros said. OSTEOPOROSIS DRUGS CAN BENEFIT HIGH-RISK ELDERLY People who experience a fracture after age 80 might benefit from medications to treat bone deterioration or weakness caused by osteoporosis, researchers reported at the Endocrine Society meeting in San Francisco. Whether to start osteoporosis drugs at that age has been debated for fear that very elderly patients could be more susceptible to the side effects. Researchers at the Cleveland Clinic reviewed medical records on 88,676 patients aged 80 and older who had suffered a fracture due to osteoporosis. Half of them had subsequently been treated with either Merck & Co.'s Fosamax, Roche and GlaxoSmithKline's Boniva, Amgen's Prolia, or Eli Lilly's Evista or Forteo. The others did not receive any osteoporosis drugs. Over the next five years, after accounting for patients' other health conditions, the hospitalization rate was 19% lower and the mortality rate was 15% lower in the group treated with bone-strengthening medications. "The results of our study support the need to enhance the individualized initiation of treatment of osteoporosis, even in people who are older than 80," study leader Dr. Gianina Flocco said in a statement. "Treating people to reduce the burden of osteoporosis complications, like fractures leading to disability or death, would play a significant role in improving health span in the growing older population."
Reuters
16-07-2025
- Health
- Reuters
Health Rounds: GLP-1 obesity drugs may boost low testosterone
July 16 (Reuters) - GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, opens new tab, the Endocrine Society's annual meeting. Weight loss from lifestyle changes or bariatric surgery is known to boost testosterone levels, but the impact of anti-obesity medications has not been widely investigated, study leader Dr. Shellsea Portillo Canales of SSM Health St. Louis University Hospital in Missouri said in a statement. Portillo Canales and colleagues tracked 110 men with obesity – many also with type 2 diabetes – who were being treated with semaglutide, dulaglutide or tirzepatide, the active ingredients in Novo Nordisk's Wegovy and Ozempic or Eli Lilly's Trulicity, Mounjaro, and Zepbound. The average age was 54. None of the men were receiving other testosterone-boosting medications. During 18 months of treatment, the proportion of men with testosterone levels in the normal range rose from 53% to 77%. Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, strength and red blood cell production. In the current study, the greater the weight loss, the greater the improvement in testosterone levels, the researchers found. While the study cannot prove GLP-1 drugs caused low testosterone levels to normalize, it does show a direct correlation, Portillo Canales noted. Popular GLP-1 anti-obesity medications are effective for weight loss even when treatment is inconsistent, new findings suggest. Patients often face challenges in accessing these medications – such as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Zepbound and Mounjaro - due to supply shortages and insurance coverage obstacles, study leader Kaelen Medeiros of privately held weight-loss company Calibrate in New York said in a statement. Medeiros and colleagues looked at how interruptions to GLP-1 medication access over the course of two years impacted weight-loss outcomes in 6,392 clients of Calibrate's online metabolic health program. Along with the drugs, the program also included intensive lifestyle interventions and coaching on diet, exercise, sleep and emotional health. Overall, 72.5% of participants experienced at least one disruption in their GLP-1 treatment and 11.1% had multiple disruptions, Medeiros reported at ENDO 2025. Participants who faced access issues reported a 13.7% weight loss within 12 months and a 14.9% loss within 24 months, on average. Those without treatment interruptions reported a 17% weight loss in 12 months and 20.1% in 24 months, on average. Even those who received no more than four treatments over 12 months also achieved clinically significant weight loss, with more than 10% change in body weight on average. 'While unpredictable GLP-1 medication access is frustrating, the good news is that our research shows effective weight loss can still be achieved if paired with appropriate lifestyle changes and coaching support,' Medeiros said. People who experience a fracture after age 80 might benefit from medications to treat bone deterioration or weakness caused by osteoporosis, researchers reported at the Endocrine Society meeting in San Francisco. Whether to start osteoporosis drugs at that age has been debated for fear that very elderly patients could be more susceptible to the side effects. Researchers at the Cleveland Clinic reviewed medical records on 88,676 patients aged 80 and older who had suffered a fracture due to osteoporosis. Half of them had subsequently been treated with either Merck & Co.'s Fosamax, Roche and GlaxoSmithKline's Boniva, Amgen's Prolia, or Eli Lilly's Evista or Forteo. The others did not receive any osteoporosis drugs. Over the next five years, after accounting for patients' other health conditions, the hospitalization rate was 19% lower and the mortality rate was 15% lower in the group treated with bone-strengthening medications. 'The results of our study support the need to enhance the individualized initiation of treatment of osteoporosis, even in people who are older than 80,' study leader Dr. Gianina Flocco said in a statement. 'Treating people to reduce the burden of osteoporosis complications, like fractures leading to disability or death, would play a significant role in improving health span in the growing older population.'
Yahoo
27-05-2025
- Business
- Yahoo
Surging Data Center Growth to Help Lower Energy Costs for PG&E Customers
Every 1,000 MW (or 1 GW) of New Electric Demand from Data Centers Could Decrease Monthly Electric Bills by 1-2% SAN JOSE, Calif., May 27, 2025 /PRNewswire/ -- Pacific Gas and Electric Company (PG&E) is seeing a huge jump in the amount of electricity needed for new data centers. These centers, which power things like cloud storage and artificial intelligence (AI), are expected to need about 8.7 gigawatts (GW) of electricity over the next 10 years. That's a big increase from the 5.5 GW PG&E reported at the end of 2024. To give an idea of how much power that is—just 1 GW can power around 750,000 homes at the same time. PG&E is also proud to be the host utility for this week's DTECH Data Centers & AI Conference in San Jose. The event brings together leaders from tech, government, and energy to talk about meeting the growing power needs of AI and data centers. PG&E leaders will speak on topics like: How AI is changing energy use How to speed up power delivery to data centers How to work better with developers and communities Mike Medeiros, Vice President, South Bay Delivery, PG&E, participates in the opening keynote today with several other utility executives to discuss load growth, reliability, and equitable data center expansion. "What differentiates the opportunity for data centers in California is a diversified set of customers and projects, excess clean power supply, and a regulatory approach which ensures that our existing residential customers will save money," Medeiros said. Of the 8.7 GW, PG&E is working on 18 new data center projects totaling approximately 1.4 GW that are in the final engineering phase (the last step before project construction starts) and projected to begin operations between 2026 and 2030. Most of these are in Silicon Valley and the greater San Francisco Bay Area, but some are also in the Central Valley and Sacramento. Growth in data center demand is good news for all PG&E customers. PG&E estimates for every 1,000 MW (or 1 GW) of new electric demand from data centers it serves, PG&E electric customers may save between 1-2% on their monthly bill in the long term, while serving those customers with some of the cleanest electricity in the United States. New energy demand from data centers allows PG&E to utilize more of its existing power infrastructure. By spreading the costs over more units of energy, each customer's dollar can go further. Looking Ahead: More Projects Across California After a successful study of data center needs in Silicon Valley last year, PG&E is now doing a follow-up study across its entire service area—70,000 square miles of Northern and Central California. In addition to the current 8.7 GW in PG&E's data center project pipeline noted in its first quarter 2025 earnings report, PG&E received 21 new data center project applications through its follow-up cluster study (launched in April 2025) totaling approximately 4.1 GW of additional power demand. PG&E is actively working with these customers through the end of the year to scope and finalize their requests. By grouping applications and projects together, rather than individually, PG&E can plan better, save money, and connect customers faster. PG&E is also working with real estate developer Westbank on a new net-zero community in downtown San Jose. Construction has started on infrastructure upgrades, and Westbank is now looking for data center partners to join the project. To learn more about PG&E's plans for the future, including how it is accelerating connecting data centers and other large loads, visit About PG&EPacific Gas and Electric Company, a subsidiary of PG&E Corporation (NYSE: PCG), is a combined natural gas and electric utility serving more than sixteen million people across 70,000 square miles in Northern and Central California. For more information, visit and View original content to download multimedia: SOURCE Pacific Gas and Electric Company
Yahoo
27-05-2025
- Business
- Yahoo
Biggest California utility sees more than 40% jump in data center interest, executive says
By Laila Kearney (Reuters) -PG&E, California's largest electric utility, has seen a jump of more than 40% this year in requests for power supplies from data center developers across the northern part of the state, an executive with the company told Reuters on Tuesday. California's Silicon Valley is one of the world's largest and oldest data center markets, but analysts have widely said that pricey land and costly electricity will limit the state's ability to capitalize on the current wave of demand for artificial intelligence data centers, which is concentrated in the middle of the country. PG&E, however, said it is seeing signs that the state still has room to run. Last month, PG&E, which delivers power and natural gas to about 16 million people in northern and central California, including Silicon Valley, launched a process for data center developers interested in connecting to the utility's system. The so-called cluster study yielded 4.1 gigawatts of interest, on top of the 8.7 gigawatts announced during the company's most recent earnings call in late April, said Mike Medeiros, PG&E's vice president of South Bay Delivery. Not only did the pipeline of prospective data centers being built within PG&E grow, but the size of the projects has also jumped since the previous year's cluster study, Medeiros said. Last year, the typical data center wanting to power up through PG&E had 50 to 100 megawatts in capacity. Current proposals are for projects of 500 megawatts to as much as 1,000 megawatts. "We're seeing quite a change in what customers are looking for, and some of that might be based on land availability or just scale and the efficiencies of building bigger," Medeiros said. Unlike earlier data centers, those for AI are used primarily for training the large language models, like ChatGPT, and can be further away from city centers. While California's older data centers are in Silicon Valley in the western part of the state, many of the new proposed developments are inland, including in Contra Costa County and the Fresno area. Not all of the data centers making inquiries are expected to ultimately connect to PG&E. Some of the top challenges in data center expansion for the utility include meeting the tight timelines by developers and operators and backlogs in the equipment needed to build out the grid. Sign in to access your portfolio
CBC
27-04-2025
- Politics
- CBC
Is the race narrowing in Poilievre's own riding? Here's what residents think
Social Sharing As reports emerge of a tightening race in Pierre Poilievre's Ottawa-area riding, Liberal and Conservative supporters are confident of their respective candidate's chances of winning. Supporters of the Liberals' Bruce Fanjoy believe they have a chance of unseating the Conservative leader in Carleton, which Poilievre has held since 2004. Meanwhile, Poilievre's supporters say they're confident he'll keep the seat. Still, both The Globe and Mail and Toronto Star reported last week the Conservatives were deploying a team of staffers to the riding to help Poilievre win a race some Ontario Progressive Conservative Party insiders have said could be closer than expected. "I would like to see Pierre Poilievre be gone from politics," said Bob Neske, who lives with his wife June in a quiet part of west Ottawa. "Bruce is a super nice guy ... We've been out canvassing almost every single day since the beginning." The retired military couple have thrown their support behind Fanjoy, who worked in business and marketing before stepping back to be a parent and volunteer. June Neske said the two of them "have historically voted Conservative" but neither could support Poilievre. Bob Neske said his opinion of Poilievre started to change in 2022 when the MP showed support for the convoy protest, which saw thousands of people descend on Ottawa with large trucks, protesting pandemic mandates and other government policies. He added he wouldn't be supporting the Liberals if former prime minister Justin Trudeau was still leader. 'I don't know if it's that close' One Conservative source told CBC News the party is confident Poilievre will take the seat, as he has for the past seven elections. For Mike Medeiros, who runs a mushroom farm in the riding and is voting Conservative, reports of a tightening race don't worry him. "I don't know if it's that close, maybe it is. I think what's happening too is we've got 91 candidates in our riding," Medeiros said, referring to the high number of protest candidates running in Carleton. Medeiros said affordability is top of mind for him this election, citing the high taxes he's had to pay for his farm. "I think the conservative voters will definitely come out and support their candidate who they've supported for the past 20 years," he told CBC. "Throughout the summer you'll see [Poilievre] in the riding. He'll pop in and buy some mushrooms once in a while ... he's definitely a great supporter of our local community." Medeiros added he hasn't yet run into Fanjoy. Huge turnout in advance voting The riding's candidates also include the NDP's Beth Prokaska, a retired music teacher, and the Green Party's Mark Watson, who's founded several businesses. Data released by Elections Canada shows nearly 44,000 votes were cast in Carleton during advanced polls, more than 40 per cent of the voters on the agency's list. While denying there's any concerns in the riding, the Conservatives added a rally in Carleton to his schedule for Sunday night. CBC asked for a comment from the Conservative leader but did not hear back by deadline. Meanwhile, Fanjoy says the race is winnable. "People will discover on election night that this is going to be a very close race," he said. "That's the message that we're telling people."
